COAST


COAST was a prospective, multi-center study conducted in the U.S. and Japan that evaluated patients with severely calcified coronary lesions treated with the Diamondback 360® Coronary Orbital Atherectomy System (OAS) Micro Crown prior to stent implantation.

Key Takeaways

  • COAST patients had a low rate of target lesion revascularization (TLR) of 6.3% at one year
  • COAST trial showed that the Diamondback 360® Coronary OAS Micro Crown was safe and effective in treating severely calcified lesions

Study Design

  • 100 patients with severely calcified lesions were enrolled at 12 sites in U.S. and 5 in Japan
  • Designed to evaluate the safety and efficacy of the Diamondback 360® Coronary OAS Micro Crown
  • Primary Safety Endpoint: Major Adverse Cardiac Events (MACE) at 30 days
  • Primary Efficacy Endpoint: Procedural Success defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE

Patient Population

 n=100
History of Diabetes38%
History of CABG11%
History of Hypertension95%
History of Dyslipidemia84%
Smoker (current or previous)73%

Study Results

Procedural Success85%
Successful Stent Delivery99%
Less than 50% residual stenosis99%
Freedom from in-hospital MACE86%

Procedural success defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE

Study Results

Coast 30 Day | amCharts
*MI = CK-MB>3X ULN.
Kaplan-Meier method used to estimate event rates.
MACE defined as cardiac death, MI, and TVR/TLR.

 

 

Coast 1 Year | amCharts
*MI = CK-MB>3X ULN.
Kaplan-Meier method used to estimate event rates.
MACE defined as cardiac death, MI, and TVR/TLR.
……………………………..
…………………………………………………………………….
…………………………………………………………………….

 

Other Studies